Changes of hematological and biochemical parameters in psoriasis patients treated with Secukinumab

Introduction: Psoriasis is a chronic inflammatory disease, not just affecting skin and joints but also associated with the development of cardiovascular diseases, metabolic sydrome. Secukinumab is demonstrated highly effective in the treatment of psoriasis, but so far, there has been few research on the effect of secukinumab treatment on hematological and blood biochemistry parameters in psoriasis patients. The correlation between the change of these parameters and the change of clinical outcomes are aslo evaluated. Objectives: To evaluate the effectiveness of secukinumab on hematological and blood biochemistry parameters in patients with psoriasis and their possible correlations in psoriasis patients under treatment with secukinumab. Methods: An observational study, evaluating the results before and after treatment was performed. Psoriasis patients were errolled when they had received treatmeat at least six months with secukinumab at the specialized clinic of the Ho Chi Minh City Hospital of Dermato-Venereology from January 1st 2022 to August 30th 2022. The available data on the disease activity (Psoriasis Area and severity Index – PASI), hematological and blood biochemistry parameters at base line and after 24 weeks of treatment were collected. Results: Neutrophil count, lymphocyte count, thrombocyte count, NLR, PLR were significantly decreased after secukinumab treatment. The mean platelet volumes were significantly increased at week 24 of treatment. There was no statistically significant difference between pre-treatment and 24 weeks after treatment with secukinumab of parameters: RBC, WBC, glucose, ure, creatine, AST, ALT, C-TP, TG, HDL-C, LDL-C. Conclusion: These analyses suggest that secukinumab can reduce inflammation parameters and have a neutral effect on glucose, liver enzymes, renal and lipid parameters.